<DOC>
	<DOCNO>NCT01235936</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy , pharmacokinetics repeat dos orally administer AKB-6548 pre-dialysis subject anemia .</brief_summary>
	<brief_title>Safety Efficacy Study AKB-6548 Subjects With Chronic Kidney Disease Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Key 18 79 year age , inclusive Chronic Kidney Disease Stage 3 Stage 4 Hemoglobin ( Hgb ) &lt; 10.5 g/dl TSAT &gt; 20 % CBC indicating normocytic red blood cell morphology Key BMI &gt; 40 Red blood cell transfusion within 12 week . Androgen therapy within previous 21 day prior study dose Therapy approve experimental erythropoiesis stimulate agent ( ESA ) within 10 week prior Screening visit Subjects meet criterion ESA resistance within previous 4 month Individual dos intravenous iron 250 mg large within past 21 day AST ALT &gt; 1.8x ULN . Alkaline phosphatase &gt; 2x ULN . Total bilirubin &gt; 1.5x ULN . Uncontrolled hypertension New York Heart Association Class III IV congestive heart failure Myocardial infarction , acute coronary syndrome , stroke within 6 month prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>